Sugi Predict

Sugi Predict / Compounds / SCHEMBL5219339

SCHEMBL5219339

SCHEMBL5219339

COc1ccc(C(=O)Cc2cc(Cl)ccn2)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NPC1 O15118 3/20 0.50
▸ RAB9A P51151 3/20 0.50
▸ LMNA P02545 1/20 0.48
▸ HTT P42858 1/20 0.48
▸ MAPT P10636 3/20 0.47
▸ MEN1 O00255 2/20 0.47
▸ KMT2A Q03164 2/20 0.47
▸ GSK3B P49841 1/20 0.46
▸ HDAC3 O15379 1/20 0.46
▸ HDAC4 P56524 1/20 0.46
▸ HDAC1 Q13547 1/20 0.46
▸ HDAC7 Q8WUI4 1/20 0.46
▸ HDAC2 Q92769 1/20 0.46
▸ HDAC10 Q969S8 1/20 0.46
▸ HDAC11 Q96DB2 1/20 0.46
▸ HDAC8 Q9BY41 1/20 0.46
▸ HDAC6 Q9UBN7 1/20 0.46
▸ HDAC9 Q9UKV0 1/20 0.46
▸ HDAC5 Q9UQL6 1/20 0.46
▸ HPGD P15428 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12465723 0.86 GSK3B (0.50) NPC1RAB9ALMNAHTTMAPT
SCHEMBL9993146 0.85 RAB9A (0.67) NPC1RAB9AMAPTGSK3BSMN1; SMN2
SCHEMBL5214600 0.81 RAB9A (0.61) NPC1RAB9AHTTMAPTMEN1
SCHEMBL5216584 0.81 SMN1; SMN2 (0.55) NPC1RAB9AHTTMAPTMEN1
SCHEMBL5216588 0.81 SMN1; SMN2 (0.55) NPC1RAB9AHTTMAPTMEN1
SCHEMBL24761247 0.81 MAPT (0.47) NPC1RAB9ALMNAHTTMAPT
SCHEMBL28950041 0.80 ALDH1A1 (0.48) NPC1RAB9ALMNAHTTMAPT
SCHEMBL6283263 0.78 RAB9A (0.66) NPC1RAB9AMAPTMEN1KMT2A
SCHEMBL11822819 0.77 SYK (0.54) NPC1RAB9ALMNAHTTMAPT
SCHEMBL28950048 0.76 RECQL (0.43) NPC1RAB9ALMNAHTTMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1423389-B1 PYRAZOLO-PYRIDINES FOR THE TREATMENT OF HERPES INFECTIONS SMITHKLINE BEECHAM CORP (US) 2007-06-06 — — EP disclosed
US-7141569-B2 Antiviral pyrazolopyridine compounds SMITHKLINE BEECHAM CORPORATION (US) 2006-11-28 — — US disclosed
US-20060235043-A1 Antiviral Pyrazolopyridine Compounds CHEUNG MUI 2006-10-19 — — US disclosed
EP-1377575-B1 ANTIVIRAL PYRAZOLOPYRIDINE COMPOUNDS SMITHKLINE BEECHAM CORP (US) 2006-07-05 — — EP disclosed
US-7030134-B2 Pyrazolopyridinyl pyridine and pyrimidine therapeutic compounds SMITHKLINE BEECHAM CORPORATION (US) 2006-04-18 — — US disclosed
US-6962914-B2 Pyrazolopyridinyl pyridine and pyrimidine therapeutic compounds SMITHKLINE BEECHAM CORPORATION (US) 2005-11-08 — — US disclosed
US-20050192303-A1 Pyrazolopyridinyl pyridine and pyrimidine therapeutic compounds GUDMUNDSSON KRISTJAN (US) 2005-09-01 — — US disclosed
US-20050192295-A1 Pyrazolopyridinyl pyridine and pyrimidine therapeutic compounds GUDMUNDSSON KRISTJAN (US) 2005-09-01 — — US disclosed
EP-1385847-B1 PYRAZOLO[1,5-A]PYRIDINE DERIVATIVES SMITHKLINE BEECHAM CORP (US) 2005-06-01 — — EP disclosed
US-20050107400-A1 Use of pyrazolopyridines as therapeutic compounds SMITHKLINE BEECHAM CORPORATION 2005-05-19 — — US disclosed
US-20040167335-A1 Antiviral pyrazolopyridine compounds SMITHKLINE BEECHAM CORPORATION 2004-08-26 — — US disclosed
US-20040142941-A1 Therapeutic compounds SMITHKLINE BEECHAM CORPORATION 2004-07-22 — — US disclosed
EP-1423389-A1 PYRAZOLO-PYRIDINES FOR THE TREATMENT OF HERPES INFECTIONS SmithKline Beecham Corporation (US) 2004-06-02 — — EP disclosed
EP-1385847-A2 PYRAZOLO[1,5-A]PYRIDINE DERIVATIVES SmithKline Beecham Corporation (US) 2004-02-04 — — EP disclosed
EP-1377575-A1 ANTIVIRAL PYRAZOLOPYRIDINE COMPOUNDS SmithKline Beecham Corporation (US) 2004-01-07 — — EP disclosed
EP-1372642-A1 USE OF PYRAZOLOPYRIDINES AS THERAPEUTIC COMPOUNDS SmithKline Beecham Corporation (US) 2004-01-02 — — EP disclosed
WO-2003022845-A1 PYRAZOLO-PYRIDINES FOR THE TREATMENT OF HERPES INFECTIONS SMITHKLINE BEECHAM CORPORATION (US) 2003-03-20 — — WO disclosed
WO-2002088124-A2 PYRAZOLO'1,5-A!PYRIDINE DERIVATIVES SMITHKLINE BEECHAM CORPORATION (US) 2002-11-07 — — WO disclosed
WO-2002083672-A1 ANTIVIRAL PYRAZOLOPYRIDINE COMPOUNDS SMITHKLINE BEECHAM CORPORATION (US) 2002-10-24 — — WO disclosed
WO-2002078701-A1 USE OF PYRAZOLOPYRIDINES AS THERAPEUTIC COMPOUNDS SMITHKLINE BEECHAM CORPORATION (US) 2002-10-10 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040142941-A1 Therapeutic compounds PCSK9, ABCB1, ABCB11 NPC1 5/4885RAB9A 1037/4885LMNA 2771/4885
US-20050192295-A1 Pyrazolopyridinyl pyridine and pyrimidine therapeutic compounds DPYD, TYMP, P2RY4 NPC1 771/4885RAB9A 1650/4885LMNA 4191/4885
US-20060235043-A1 Antiviral Pyrazolopyridine Compounds TYMP, DPYD, EIF2AK2 NPC1 1110/4885RAB9A 1726/4885LMNA 4023/4885
US-20050107400-A1 Use of pyrazolopyridines as therapeutic compounds QDPR, DPYD, ENTPD5 NPC1 1363/4885RAB9A 3472/4885LMNA 4093/4885
US-20050192303-A1 Pyrazolopyridinyl pyridine and pyrimidine therapeutic compounds DPYD, TYMP, P2RY4 NPC1 771/4885RAB9A 1650/4885LMNA 4191/4885
US-20040167335-A1 Antiviral pyrazolopyridine compounds TYMP, ZC3HAV1, DPYD NPC1 515/4885RAB9A 2364/4885LMNA 3853/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.